Becton, Dickinson and Company (NYSE:BDX) Posts Earnings Results

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04, RTT News reports. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm posted $3.42 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. Becton, Dickinson and Company updated its FY 2025 guidance to 14.250-14.600 EPS and its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Stock Down 3.8 %

NYSE:BDX traded down $9.06 during trading hours on Thursday, reaching $231.00. The company’s stock had a trading volume of 1,620,127 shares, compared to its average volume of 1,380,382. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company has a market cap of $66.77 billion, a price-to-earnings ratio of 49.40, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $257.58. The business’s 50-day moving average is $237.53 and its 200-day moving average is $235.16.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.80%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is currently 78.19%.

Wall Street Analyst Weigh In

Several research firms have issued reports on BDX. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.